Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 27 Apr 2023
In the second week of life, 83 percent of newborns who were fed formula milk had Clostridium difficile and Clostridium perfringens, but by the end of the third week, all infants had these infections.
Read Full NewsExtended-release buprenorphine injections increase the number of opioid-free days primarily via direct pathways and by suppressing need-related craving, a causal mediation analysis shows.
Moderate-to-severe fatty pancreas is independently linked to a higher risk for incident type 2 diabetes and chronic kidney disease.
1.
We don't all need regular skin cancer screening?but you can know your risk and check yourself
2.
A computer-aided diagnostic system for improved detection of breast cancer.
3.
Cancer Patients Are Receiving More and More Stupid Immunotherapy.
4.
Dual imaging capsule captures 3D tissue and blood vessel changes for early esophageal cancer diagnosis
5.
Tumor characteristics found to differ for melanomas in children, teens and young adults
1.
Unveiling the Mystery of Epstein-Barr Virus: What We Know So Far
2.
Sound Waves and Self-Destruction: A Promising Nanotech Weapon in the Fight Against Cancer
3.
The Power of White Blood Cells: How They Help Keep Us Healthy
4.
Emerging Dysregulated Signaling Pathways in Early-Onset Colorectal Cancer
5.
How Should We Approach Solid Pseudopapillary Neoplasm of the Pancreas with Hepatic Metastases?
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part III
2.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VI
3.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part II
4.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part I
5.
Treatment Paradigm for Patients with R/R Adult B-cell ALL- Expert Discussions
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge